Fusion-VAC-XS15
Phase 1Small molecule
Fusion-VAC-XS15 is one of 8 small molecule programs targeting Immune Checkpoint Inhibition. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Immune Checkpoint Inhibition
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Tecentriq
RochePhase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Tiragolumab
RochePhase 2
BMS-986253
Bristol-Myers SquibbPhase 2
BMS-986016
Bristol-Myers SquibbPhase 2
Fusion-VAC-XS15
UUniversity Hospital Tuebingen
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fusion-VAC-XS15. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity Hospital Tuebingen